Your browser is no longer supported. Please, upgrade your browser.
ABUS Arbutus Biopharma Corporation daily Stock Chart
ABUS [NASD]
Arbutus Biopharma Corporation
Index- P/E- EPS (ttm)-2.68 Insider Own30.16% Shs Outstand67.68M Perf Week-7.26%
Market Cap152.94M Forward P/E- EPS next Y-0.85 Insider Trans0.00% Shs Float44.46M Perf Month87.07%
Income-155.70M PEG- EPS next Q-0.23 Inst Own38.70% Short Float0.92% Perf Quarter-25.68%
Sales6.80M P/S22.49 EPS this Y-137.80% Inst Trans9.63% Short Ratio0.37 Perf Half Y29.94%
Book/sh-0.99 P/B- EPS next Y-8.40% ROA-120.30% Target Price- Perf Year19.23%
Cash/sh1.20 P/C1.80 EPS next 5Y- ROE416.80% 52W Range0.82 - 3.66 Perf YTD-21.94%
Dividend- P/FCF- EPS past 5Y-9.90% ROI203.20% 52W High-40.71% Beta2.64
Dividend %- Quick Ratio21.90 Sales past 5Y-16.70% Gross Margin- 52W Low164.18% ATR0.22
Employees80 Current Ratio21.90 Sales Q/Q114.30% Oper. Margin- RSI (14)67.37 Volatility7.77% 14.08%
OptionableYes Debt/Eq- EPS Q/Q46.60% Profit Margin- Rel Volume0.40 Prev Close2.16
ShortableYes LT Debt/Eq- EarningsMay 11 BMO Payout- Avg Volume1.11M Price2.17
Recom1.90 SMA2022.56% SMA5047.53% SMA20013.92% Volume450,563 Change0.46%
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Oct-04-19Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18Upgrade B. Riley FBR Neutral → Buy $11.50 → $9
Oct-15-18Upgrade Wedbush Underperform → Neutral $5
Oct-12-18Reiterated Chardan Capital Markets Buy $12 → $6.50
Jul-06-18Downgrade B. Riley FBR, Inc. Buy → Neutral $9 → $9
Mar-19-18Resumed Chardan Capital Markets Buy $8.25
Mar-19-18Downgrade Wedbush Outperform → Neutral $9 → $6
Jan-05-18Initiated B. Riley FBR, Inc. Buy $10
Apr-04-17Upgrade Chardan Capital Markets Neutral → Buy $3 → $6
Feb-01-17Reiterated Wedbush Outperform $13 → $10
Dec-13-16Downgrade Chardan Capital Markets Buy → Neutral $4 → $3
Nov-30-16Upgrade Chardan Capital Markets Neutral → Buy $4
Oct-14-16Upgrade Chardan Capital Markets Sell → Neutral $3
Aug-05-16Downgrade Leerink Partners Outperform → Mkt Perform
Jul-08-16Downgrade Chardan Capital Markets Neutral → Sell $3.25 → $2.75
May-27-20 08:00AM  Arbutus to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-20-20 01:18PM  Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More Zacks
May-19-20 11:11AM  P/E Ratio Insights for Arbutus Biopharma Benzinga +23.53%
May-18-20 04:05PM  Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg GlobeNewswire -10.95%
06:05AM  Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically Simply Wall St.
May-15-20 11:04AM  Why Arbutus (ABUS) Stock Might be a Great Pick Zacks +14.13%
09:15AM  Arbutus' Shares March Higher, Can It Continue? Zacks
May-14-20 02:22PM  3 Strong Buy Penny Stocks With Triple-Digit Upside TipRanks +8.24%
May-12-20 08:00AM  Arbutus to Present at UBS Virtual Global Healthcare Conference GlobeNewswire +14.58%
May-11-20 11:19AM  Moving Average Crossover Alert: Arbutus Biopharma Zacks +6.67%
07:45AM  Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:12AM  Arbutus Biopharma: Q1 Earnings Insights Benzinga
06:00AM  Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections GlobeNewswire
May-04-20 08:00AM  Arbutus to Report First Quarter 2020 Financial Results GlobeNewswire +13.08%
Apr-27-20 12:32PM  Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know Zacks
Mar-31-20 08:47AM  Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't? Zacks -9.82%
06:16AM  The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Mar-27-20 08:02AM  The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance Benzinga -46.46%
Mar-26-20 04:05PM  Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B GlobeNewswire +5.12%
Mar-05-20 08:55AM  Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:30AM  Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update GlobeNewswire
Feb-27-20 12:30PM  Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks +10.71%
08:00AM  Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results GlobeNewswire
Feb-10-20 08:00AM  Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer GlobeNewswire
Jan-02-20 05:05AM  Does The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Price Tend To Follow The Market? Simply Wall St. +5.76%
Dec-30-19 10:08AM  Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock Zacks +9.64%
Dec-27-19 09:04AM  Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down Zacks
Dec-19-19 03:50PM  Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See Mode Insider Monkey
Nov-06-19 09:35AM  Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM  Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 07:13AM  We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate Simply Wall St.
Oct-30-19 10:33AM  Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know Zacks
07:30AM  Arbutus to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-10-19 02:59PM  Bucks biopharm firm halts study of potential hepatitis B cure American City Business Journals
Oct-04-19 07:32AM  The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga -28.67%
Oct-03-19 04:05PM  Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Globenewswire Test
04:05PM  Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B GlobeNewswire
Sep-26-19 07:30AM  Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire -6.25%
Sep-19-19 06:17AM  Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop? Simply Wall St.
Aug-20-19 04:05PM  Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors GlobeNewswire
Aug-06-19 07:30AM  Arbutus to Participate at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 08:55AM  Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:30AM  Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-29-19 07:30AM  Arbutus to Report Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 10:34AM  Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-15-19 04:05PM  Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B GlobeNewswire
Jul-04-19 04:09PM  Heres What Hedge Funds Think About Arbutus Biopharma Corp (ABUS) Insider Monkey
Jul-03-19 07:31AM  The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief Benzinga -5.26%
Jul-02-19 04:01PM  Arbutus Sells Part of its ONPATTRO (patisiran) Royalty Interest to OMERS GlobeNewswire
Jun-21-19 09:20AM  Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up Zacks -6.78%
Jun-20-19 07:30AM  Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729 GlobeNewswire +37.21%
Jun-17-19 07:30AM  Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. GlobeNewswire +24.66%
Jun-13-19 08:30AM  Arbutus to Participate at JMP Securities Life Sciences Conference GlobeNewswire
May-22-19 12:56PM  Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO? Simply Wall St. -10.30%
May-13-19 08:30AM  Arbutus to Present at Upcoming May 2019 Conferences GlobeNewswire -6.38%
May-06-19 05:15PM  Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:45PM  Arbutus: 1Q Earnings Snapshot Associated Press
04:01PM  Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-29-19 08:30AM  Arbutus to Report First Quarter 2019 Financial Results GlobeNewswire
Apr-25-19 10:33AM  Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -5.84%
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-08-19 08:37AM  Top Ranked Momentum Stocks to Buy for April 8th Zacks
Apr-04-19 03:03PM  Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last? Simply Wall St. +6.22%
Mar-07-19 10:26PM  Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives GlobeNewswire
Feb-28-19 08:30AM  Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update GlobeNewswire
Feb-04-19 07:35AM  Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-22-19 10:13AM  Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register? Simply Wall St.
Dec-23-18 03:40AM  Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)? Insider Monkey
Dec-11-18 07:55AM  New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-08-18 10:03PM  Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy? Insider Monkey
Dec-05-18 11:20AM  Why Arbutus Biopharma Corporations (NASDAQ:ABUS) CEO Pay Matters To You Simply Wall St.
Nov-26-18 04:41PM  Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors GlobeNewswire -5.60%
Nov-21-18 08:41AM  Options Traders Expect Huge Moves in Arbutus (ABUS) Stock Zacks +5.17%
Nov-07-18 04:01PM  Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-18 08:30AM  Arbutus to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-22-18 08:30AM  Arbutus Names New Members to its Board of Directors GlobeNewswire
Oct-19-18 08:25AM  New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-17-18 02:25PM  What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)? Simply Wall St.
Oct-10-18 10:23AM  Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks -23.83%
08:00AM  Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics ACCESSWIRE
Oct-09-18 03:23PM  Here's Why Arbutus Biopharma Corp. Is Tanking Today Motley Fool -33.99%
08:30AM  Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer GlobeNewswire
Oct-02-18 08:30AM  Arbutus to Present at Chardans Genetic Medicines Conference GlobeNewswire
Sep-24-18 09:00AM  Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock? Zacks
Aug-28-18 08:30AM  Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference GlobeNewswire
Aug-21-18 07:35AM  Consolidated Research: 2018 Summary Expectations for GSV Capital, NantHealth, Gold Fields, Sogou Inc. Sponsored ADR, Clementia Pharmaceuticals, and Arbutus Biopharma Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-13-18 08:30AM  Arbutus LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis GlobeNewswire
Aug-09-18 08:30AM  Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 04:00PM  Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Arbutus Biopharma Corporation to Host Earnings Call ACCESSWIRE
Jul-20-18 09:31AM  Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue? Zacks
Jul-19-18 10:26AM  Harry Boxers three drug stocks to watch MarketWatch
08:30AM  Arbutus to Report Second Quarter 2018 Financial Results GlobeNewswire
Jul-14-18 02:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-12-18 12:54PM  Harry Boxers four health-care stocks to watch MarketWatch +8.49%
Jul-10-18 07:00AM  Arbutus Presents Corporate Update on Key Milestones GlobeNewswire
Jul-07-18 07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-06-18 10:59AM  Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run Benzinga
09:02AM  Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6% Zacks
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.